Other multigene prognostic tests approved for use in ER + /HER2− breast cancer such as MammaPrint, Prosigna PAM50, Endopredict and the Breast Cancer Index exist but are generally less widely used in routine clinical practice in North America, and are approved to estimate recurrence up to 5–10 years, similar to Oncotype13,14. Here, ESR1 is linked to breast carcinoma.